Lps priming of stromal cells to generate lps-specific exosome educated macrophages
US-2019249144-A1 · Aug 15, 2019 · US
Treatment of disc degenerative disease and stimulation of proteoglycan synthesis by fibroblast conditioned media and formulations thereof
US11732239B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11732239-B2 |
| Application number | US-202017022897-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 16, 2020 |
| Priority date | Sep 16, 2019 |
| Publication date | Aug 22, 2023 |
| Grant date | Aug 22, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In some aspects, disclosed are methods and compositions for disc regeneration and/or repair using one or more components from conditioned media from fibroblasts. In certain cases, conditioned media is obtained from fibroblasts stimulated with one or more opioid receptor antagonists and one or more toll-like receptor agonists. Conditioned media from fibroblasts may be provided in an effective amount to an individual in need thereof.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of promoting disc regeneration in an individual, the method comprising providing to the individual an effective amount of one or more components derived from a fibroblast cell cultured with one or more opioid receptor antagonists and one or more toll-like receptor (TLR) agonists. 2. The method of claim 1 , wherein the one or more components are derived from media from culture of the fibroblast cells. 3. The method of claim 2 , wherein the fibroblast cells were cultured with the one or more opioid receptor antagonists and the one or more TLR agonists in a proliferative state. 4. The method of claim 2 , wherein the one or more components are administered to the individual intradiscally. 5. The method of claim 2 , wherein the one or more components are administered to the individual systemically. 6. The method of claim 1 , wherein the one or more components comprise exosomes. 7. The method of claim 6 , wherein the exosomes comprises CD9. 8. The method of claim 6 , wherein the exosomes are capable of binding to a dendritic cell and/or a mesenchymal stem cell.
Assignees
Inventors
Classifications
Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00) · CPC title
Dendritic cells, e.g. Langherhans cells in the epidermis · CPC title
- C12N5/0656Primary
Adult fibroblasts · CPC title
- A61K35/33Primary
Fibroblasts · CPC title
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11732239B2 cover?
- In some aspects, disclosed are methods and compositions for disc regeneration and/or repair using one or more components from conditioned media from fibroblasts. In certain cases, conditioned media is obtained from fibroblasts stimulated with one or more opioid receptor antagonists and one or more toll-like receptor agonists. Conditioned media from fibroblasts may be provided in an effective am…
- Who is the assignee on this patent?
- Figene Llc
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0656. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).